Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) CEO Jay R. Luly Sells 5,142 Shares

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) CEO Jay R. Luly sold 5,142 shares of the firm’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $8.06, for a total value of $41,444.52. Following the completion of the transaction, the chief executive officer now directly owns 801,638 shares in the company, valued at $6,461,202.28. This trade represents a 0.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Enanta Pharmaceuticals Stock Performance

Shares of Enanta Pharmaceuticals stock traded down $0.30 on Tuesday, hitting $8.64. 429,363 shares of the company traded hands, compared to its average volume of 209,776. Enanta Pharmaceuticals, Inc. has a 52 week low of $7.58 and a 52 week high of $17.80. The business has a 50-day simple moving average of $10.51 and a 200 day simple moving average of $12.04. The stock has a market capitalization of $183.08 million, a P/E ratio of -1.58 and a beta of 0.49.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings results on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.20). The company had revenue of $14.60 million during the quarter, compared to the consensus estimate of $17.99 million. Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. The business’s revenue was down 22.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.33) earnings per share. Research analysts expect that Enanta Pharmaceuticals, Inc. will post -4.81 earnings per share for the current year.

Institutional Trading of Enanta Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC bought a new position in shares of Enanta Pharmaceuticals during the 2nd quarter valued at approximately $35,000. US Bancorp DE raised its stake in Enanta Pharmaceuticals by 4,933.7% during the third quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 4,243 shares in the last quarter. Quest Partners LLC raised its stake in Enanta Pharmaceuticals by 511.2% during the second quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company’s stock valued at $150,000 after purchasing an additional 9,692 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in Enanta Pharmaceuticals during the third quarter valued at $122,000. Finally, Valence8 US LP purchased a new position in shares of Enanta Pharmaceuticals in the 3rd quarter worth $207,000. Institutional investors own 94.99% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on ENTA shares. HC Wainwright restated a “buy” rating and set a $27.00 target price on shares of Enanta Pharmaceuticals in a research note on Thursday, October 10th. Robert W. Baird decreased their price objective on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 26th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $21.00 target price (down previously from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $19.50.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.